PMV Pharmaceuticals (NASDAQ:PMVP) Shares Gap Down to $12.53

PMV Pharmaceuticals, Inc. (NASDAQ:PMVPGet Rating) gapped down before the market opened on Tuesday . The stock had previously closed at $12.53, but opened at $12.19. PMV Pharmaceuticals shares last traded at $12.17, with a volume of 797 shares.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Oppenheimer raised their price objective on shares of PMV Pharmaceuticals from $30.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, June 9th. HC Wainwright reissued a “buy” rating and set a $63.00 price target on shares of PMV Pharmaceuticals in a research note on Wednesday, June 8th.

PMV Pharmaceuticals Stock Performance

The company’s 50 day moving average price is $14.54 and its 200 day moving average price is $15.30.

Hedge Funds Weigh In On PMV Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC bought a new position in PMV Pharmaceuticals in the first quarter valued at approximately $25,000. Quantbot Technologies LP bought a new position in PMV Pharmaceuticals in the second quarter valued at approximately $26,000. US Bancorp DE boosted its position in shares of PMV Pharmaceuticals by 2,588.0% during the first quarter. US Bancorp DE now owns 2,016 shares of the company’s stock worth $42,000 after purchasing an additional 1,941 shares in the last quarter. Russell Investments Group Ltd. bought a new position in shares of PMV Pharmaceuticals during the second quarter worth $30,000. Finally, Point72 Hong Kong Ltd bought a new position in shares of PMV Pharmaceuticals during the fourth quarter worth $87,000.

About PMV Pharmaceuticals

(Get Rating)

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function.

Further Reading

Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.